Monday, September 26, 2016 10:26:28 AM
...There appear to be no leaks of inside information. AMAZING!
THIS IS THE WAY IT IS SUPPOSED TO BE. CLRB IS THE REAL DEAL. GOOD LUCK TO ALL LONGS!
Cellectar Biosciences, Inc.
Sep 19, 2016 8:30 AM
GlobeNewswire
????
MADISON, Wis., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016, which will be held at the Sofitel Hotel at 45 West 44th Street in New York City.
“The Ladenburg Thalmann Healthcare Conference is a well respected gathering of investors focused specifically on the healthcare and life sciences space, providing a unique venue for companies such as Cellectar to present to an educated audience,” said Mr. Caruso. “We look forward to reviewing the company’s continued operational successes along with our research and development advancements.”
The company’s presentation will be held in the Madeleine Room (Track 6) at 2:30 PM ET and will be webcast via http://wsw.com/webcast/ladenburg2/clrb. Mr. Caruso’s presentation will also be archived and available for playback on the company’s website, http://www.cellectar.com, in the Investor Relations section.
Recent CLRB News
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2024 10:40:00 AM
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 10:40:00 AM
- Cellectar Biosciences to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/14/2024 12:52:48 PM
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer • GlobeNewswire Inc. • 03/04/2024 11:40:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:31:57 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:29:43 PM
- Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:03:04 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 01:00:28 PM
- Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study • GlobeNewswire Inc. • 01/30/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:30:40 PM
- Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million • GlobeNewswire Inc. • 01/25/2024 11:40:00 AM
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient • GlobeNewswire Inc. • 01/22/2024 11:40:00 AM
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data • GlobeNewswire Inc. • 01/16/2024 11:40:00 AM
- Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results • GlobeNewswire Inc. • 01/12/2024 11:44:16 AM
- Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting • GlobeNewswire Inc. • 01/11/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 11:02:18 AM
- Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
- Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:09:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:07:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:05:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 01:04:10 AM
- Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform • GlobeNewswire Inc. • 12/12/2023 01:30:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM